Aspen Aerogels Inc. (NYSE:ASPN) was downgraded by stock analysts at Citigroup Inc. from a “buy” rating to a “neutral” rating in a report released on Monday.

Other equities research analysts have also recently issued research reports about the company. Craig Hallum started coverage on Aspen Aerogels in a research note on Tuesday, September 20th. They issued a “buy” rating and a $10.00 target price on the stock. Canaccord Genuity restated a “buy” rating and issued a $8.50 target price on shares of Aspen Aerogels in a research note on Thursday, August 4th. Needham & Company LLC restated a “buy” rating and issued a $8.00 target price (down previously from $9.50) on shares of Aspen Aerogels in a research note on Friday, November 4th. Zacks Investment Research upgraded Aspen Aerogels from a “sell” rating to a “hold” rating in a research note on Wednesday, October 5th. Finally, Seaport Global Securities cut Aspen Aerogels from a “buy” rating to a “neutral” rating in a research note on Friday, November 4th. One analyst has rated the stock with a sell rating, three have assigned a hold rating and four have given a buy rating to the company. The stock currently has a consensus rating of “Hold” and a consensus price target of $7.75.

Analyst Recommendations for Aspen Aerogels (NYSE:ASPN)

Shares of Aspen Aerogels (NYSE:ASPN) opened at 3.94 on Monday. The stock has a 50 day moving average of $5.76 and a 200 day moving average of $4.98. The firm’s market cap is $81.09 million. Aspen Aerogels has a 52 week low of $3.38 and a 52 week high of $6.85.

Aspen Aerogels (NYSE:ASPN) last released its quarterly earnings data on Thursday, November 3rd. The company reported ($0.13) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.09) by $0.04. Aspen Aerogels had a negative net margin of 3.64% and a negative return on equity of 3.82%. The business had revenue of $29.60 million for the quarter, compared to the consensus estimate of $29.05 million. During the same quarter last year, the firm earned ($0.11) EPS. The company’s revenue for the quarter was down 6.0% on a year-over-year basis. Equities analysts forecast that Aspen Aerogels will post ($0.41) earnings per share for the current year.

In related news, Director Richard F. Reilly acquired 10,000 shares of the company’s stock in a transaction dated Tuesday, August 23rd. The shares were bought at an average price of $4.82 per share, for a total transaction of $48,200.00. Following the purchase, the director now directly owns 36,178 shares in the company, valued at approximately $174,377.96. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, Director William P. Noglows acquired 20,000 shares of the company’s stock in a transaction dated Wednesday, August 24th. The shares were bought at an average price of $4.98 per share, for a total transaction of $99,600.00. Following the purchase, the director now owns 46,178 shares in the company, valued at $229,966.44. The disclosure for this purchase can be found here. Insiders own 14.70% of the company’s stock.

Several large investors have recently made changes to their positions in the company. Balter Liquid Alternatives LLC boosted its stake in shares of Aspen Aerogels by 162.8% in the first quarter. Balter Liquid Alternatives LLC now owns 33,236 shares of the company’s stock worth $150,000 after buying an additional 20,590 shares in the last quarter. Firsthand Capital Management Inc. boosted its stake in shares of Aspen Aerogels by 16.7% in the second quarter. Firsthand Capital Management Inc. now owns 35,000 shares of the company’s stock worth $174,000 after buying an additional 5,000 shares in the last quarter. TD Asset Management Inc. boosted its stake in shares of Aspen Aerogels by 9.3% in the third quarter. TD Asset Management Inc. now owns 35,200 shares of the company’s stock worth $210,000 after buying an additional 3,000 shares in the last quarter. Mesirow Financial Investment Management Equity Management bought a new stake in shares of Aspen Aerogels during the third quarter worth about $216,000. Finally, GSA Capital Partners LLP boosted its stake in shares of Aspen Aerogels by 71.6% in the second quarter. GSA Capital Partners LLP now owns 44,129 shares of the company’s stock worth $219,000 after buying an additional 18,419 shares in the last quarter. Institutional investors own 79.09% of the company’s stock.

About Aspen Aerogels

Aspen Aerogels, Inc is an energy technology company that designs, develops and manufactures aerogel insulation used primarily in energy infrastructure facilities. The Company also performs contract research services for various federal and non-federal government agencies, including the Department of Defense, the Department of Energy and other institutions.

5 Day Chart for NYSE:ASPN

Receive News & Stock Ratings for Aspen Aerogels Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aspen Aerogels Inc. and related stocks with our FREE daily email newsletter.